Sudipto Ganguly, PhD, joined the Johns Hopkins University School of Medicine faculty in June, 2019 as an Assistant Professor in the Cancer Immunology Program (Department of Oncology). He received his B.S. (Honors in Botany) and M.S. (Genetics and Plant Breeding) degrees from the University of Calcutta in India. He received his Ph.D. in Biochemistry from the University of Calcutta, where he was supervised by Professor Mitali Chatterjee, MD, PhD. His doctoral research investigated the role of systemic and intra-lesional cytokines in the immune-pathology of post-Kala-azar dermal leishmaniasis (PKDL). During his post-doctoral training in the laboratory of Professor Leo Luznik, MD, at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Dr. Ganguly showed the efficacy of post-transplant cyclophosphamide against Graft-versus-Host-Disease (GVHD) was dependent on induction, maintenance and expansion of thymic-derived T regulatory cells. His lab is studying novel, in silico-predicted, immune checkpoint targets by expression analysis in clinical samples as well as in syngeneic tumor models in both global and conditional gene-knockout mice. His group have recently characterized PVRIG (Poliovirus Related Immunoglobulin Domain Containing) as a novel cancer-specific immune checkpoint in both mice and humans. He has further shown that PVRL2, the principal ligand of PVRIG, is expressed copiously by infiltrating myeloid cells in the tumor micro-environment, particularly in high-grade serous ovarian cancer, making the PVRIG-PVRL2 axis a target of interest for immunotherapy. He is a recipient of the NCI Ovarian Cancer SPORE CEP award.